NCT02172755View on ClinicalTrials.gov

Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

August 31, 2002

Study Completion Date

August 31, 2002

Conditions
Epilepsy
Interventions
DRUG

BIA 2-093

During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.

Trial Locations (1)

D-22525

Scope International Life Sciences AG,, Hamburg

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02172755 - Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites | Biotech Hunter | Biotech Hunter